These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24987862)

  • 21. Analysis of the prevalence of dyslipidemia in individuals with HIV and its association with antiretroviral therapy.
    Limas TG; Pinto Gde A; Marcato LM; Coelho DR
    Rev Soc Bras Med Trop; 2014; 47(5):547-51. PubMed ID: 25467253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.
    Floris-Moore M; Howard AA; Lo Y; Schoenbaum EE; Arnsten JH; Klein RS
    AIDS Patient Care STDS; 2007 Jul; 21(7):479-91. PubMed ID: 17651029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.
    Liu E; Armstrong C; Spiegelman D; Chalamilla G; Njelekela M; Hawkins C; Hertzmark E; Li N; Aris E; Muhihi A; Semu H; Fawzi W
    Clin Infect Dis; 2013 Jun; 56(12):1820-8. PubMed ID: 23449270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.
    Wang T; Yi R; Green LA; Chelvanambi S; Seimetz M; Clauss M
    Cardiovasc Pathol; 2015; 24(5):279-82. PubMed ID: 26233281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of darunavir on lipid profile in HIV-infected patients.
    Overton ET; Arathoon E; Baraldi E; Tomaka F
    HIV Clin Trials; 2012; 13(5):256-70. PubMed ID: 23134626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid management in patients who have HIV and are receiving HIV therapy.
    Aberg JA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):207-22. PubMed ID: 19217520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.
    Tarr PE; Rotger M; Telenti A
    Pharmacogenomics; 2010 Apr; 11(4):587-94. PubMed ID: 20350140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review.
    Souza SJ; Luzia LA; Santos SS; Rondó PH
    Rev Assoc Med Bras (1992); 2013; 59(2):186-98. PubMed ID: 23582562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nurse practitioner's role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy.
    Willard S
    J Assoc Nurses AIDS Care; 2006; 17(1):7-17. PubMed ID: 16686080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir).
    Domingos H; da Cunha RV; Paniago AM
    Braz J Infect Dis; 2007 Apr; 11(2):290-2. PubMed ID: 17625780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
    Troll JG
    Curr Atheroscler Rep; 2011 Feb; 13(1):51-6. PubMed ID: 21181310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic.
    Pinto Neto LF; das Neves MB; Ribeiro-Rodrigues R; Page K; Miranda AE
    Braz J Infect Dis; 2013; 17(4):438-43. PubMed ID: 23735423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
    Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE;
    Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.
    Neto MG; Zwirtes R; Brites C
    Braz J Infect Dis; 2013; 17(6):691-700. PubMed ID: 23916459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.
    Lagathu C; Béréziat V; Gorwood J; Fellahi S; Bastard JP; Vigouroux C; Boccara F; Capeau J
    Expert Opin Drug Saf; 2019 Sep; 18(9):829-840. PubMed ID: 31304808
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV infection and lipids.
    Jain A; Kolvekar T; Nair DR
    Curr Opin Cardiol; 2018 Jul; 33(4):429-435. PubMed ID: 29601329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyslipidemia in HIV-infected individuals.
    Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
    Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.
    Kelesidis T; Currier JS
    Endocrinol Metab Clin North Am; 2014 Sep; 43(3):665-84. PubMed ID: 25169560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.